CASE STUDIES
NemaLife has launched BioSēq™, a next-generation transcriptomics platform that maps how bioactive ingredients affect gene expression and signaling pathways tied to conserved health outcomes, providing deep mechanistic insight to complement high-throughput phenotypic screening.
NemaLife’s Discovery Flywheel and Efficacy Matrix use an AI-powered organism-on-chip platform with C. elegans to rapidly profile bioactive ingredients across multiple key health benefits—simultaneously.
C. elegans is emerging as a powerful alternative to mice in early preclinical research due to its simplicity, speed, cost-efficiency, and deep biological relevance, enabling high-throughput insights into human biology and disease that are difficult or slow to obtain with mammalian models.